Experimental studies have illustrated that TP53 mutations can accelerate tumorigenesis by interacting with the nuclease Mre11 and disrupting the Mre11–rad50–nbs1 complex, thereby inhibiting the activation of ataxia telangiectasia mutated.25 Here, MRE11 is linked to telangiectasis.